Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 19/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4217791 | 0.88 | CETP (0.36) | CETP | |
| SCHEMBL4234332 | 0.86 | CETP (0.35) | CETP | |
| SCHEMBL4225954 | 0.85 | CETP (0.33) | CETPCHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4223074 | 0.84 | CETP (0.33) | CETP | |
| SCHEMBL4225948 | 0.83 | CETP (0.34) | CETP | |
| SCHEMBL4223986 | 0.82 | CETP (0.35) | CETP | |
| SCHEMBL5623716 | 0.81 | CETP (0.36) | CETP | |
| SCHEMBL5623988 | 0.79 | CETP (0.35) | CETP | |
| SCHEMBL5628709 | 0.78 | CETP (0.34) | CETP | |
| SCHEMBL5624903 | 0.78 | CETP (0.35) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
| EP-1968941-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007073934-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | CETP, PCSK9, MTTP | CETP 1/4885CHRNB1 2654/4885CHRNB2 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.